CSL: Result 2014

CSL has reported another respectable result thanks to increasing sales from its immunology powerhouse.

CSL has reported a respectable full-year result, with revenue increasing 9% in constant currency terms to US$5.5bn due to strong demand for its antibody, albumin and specialty products. Net profit increased 8% to US$1.3bn, while earnings per share rose 11% to US$2.70 thanks to CSL’s ongoing share buyback. A final unfranked dividend of $0.60 was declared (ex date 8 Sep), bringing the annual total to $1.24, for a yield of 1.8%.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles